Document is current
Any future updates will be listed below
-
Authors
Barone, Jordan C. https://orcid.org/0000-0002-5999-0921
Romano, Raffaele https://orcid.org/0009-0005-1883-186X
Nagpal, Anisha https://orcid.org/0000-0001-7111-9322
Salerno, Antonio https://orcid.org/0009-0000-2191-6155
Patterson, Anna https://orcid.org/0009-0000-7845-182X
Wenzel, Elizabeth S. https://orcid.org/0000-0002-7732-608X
Guzman, Gabriela
Alluri, Viraja
Maki, Pauline
Pinna, Graziano https://orcid.org/0000-0001-7541-4855
Eisenlohr-Moul, Tory A. https://orcid.org/0000-0002-9231-3105
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (T32MH067631)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (RF1MH120843)
U.S. Department of Defense (HT9425-25-1-0261)
U.S. Department of Health & Human Services | National Institutes of Health (R01MH134904)
- License Information
-
More Information
Article History
Received: 30 June 2024
Revised: 28 October 2025
Accepted: 14 November 2025
First Online: 20 December 2025
Competing interests
: Coauthor Graziano Pinna was a paid consultant to PureTech Health, GABA Therapeutics, and NeuroTrauma Sciences. He has two patent applications, one on PEA and PPAR-a agonists (US20180369171A1, granted on May 16, 2023) and one on allopregnanolone analogs (US11266663B2, granted on March 8, 2022) in the treatment of neuropsychiatric disorders.
: All methods were performed in accordance with the relevant guidelines and regulations. This study received approval from the University of Illinois Chicago Institutional Review Board (IRB) under approval number 2019-0624 and was registered with ClinicalTrials.gov (NCT04112368). All participants provided informed consent.
